Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22160460 | 0.85 | APOL1 (0.49) | APOL1 | |
| SCHEMBL30184436 | 0.85 | APOL1 (0.49) | APOL1 | |
| SCHEMBL22118435 | 0.85 | APOL1 (0.38) | APOL1 | |
| SCHEMBL29952794 | 0.81 | APOL1 (0.52) | APOL1 | |
| SCHEMBL28863435 | 0.80 | APOL1 (0.48) | APOL1 | |
| SCHEMBL22118353 | 0.77 | MEN1 (0.52) | — | |
| SCHEMBL24098777 | 0.77 | APOL1 (0.66) | APOL1 | |
| SCHEMBL30218335 | 0.77 | APOL1 (0.66) | APOL1 | |
| SCHEMBL24099167 | 0.77 | APOL1 (0.66) | APOL1 | |
| SCHEMBL30218285 | 0.77 | APOL1 (0.66) | APOL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801234-B2 | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230250087-A1 | SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-10 | — | — | US | disclosed |
| EP-4165036-A1 | SOLID FORMS OF APOL1 INHIBITOR AND USING THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4165023-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115867543-A | Solid forms of an APOL1 inhibitor and methods of use thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| CN-115209894-A | Method for treating APOL-1 dependent focal segmental glomerulosclerosis | 弗特克斯药品有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252863-A1 | SOLID FORMS OF APOL1 INHIBITOR AND USING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453760-A | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2021178768-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210275496-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-09-09 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | APOL1 1/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | APOL1 1/4885 |
| US-11801234-B2 | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis | APOL1, APOB, NPC1L1 | APOL1 1/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | APOL1 1/4885 |
| US-20230250087-A1 | SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME | APOL1, ACSL1, SAAL1 | APOL1 1/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | APOL1 1/4885 |
| US-20210275496-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | APOL1, APOB, NPC1L1 | APOL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.